Compass Therapeutics announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors. “Dosing the first patient in the CTX-8371 Phase 1 represents the advancement of our third program into the clinic, which is an important milestone for the company,” said Vered Bisker-Leib, PhD, Chief Executive Officer. “We recently published preclinical data in the peer-reviewed journal, OncoImmunology, supporting the novel mechanism of action of CTX-8371: proteolytic cleavage and subsequent loss of cell surface PD-1. We believe this mechanism drives the enhanced anti-tumor activity of CTX-8371 in preclinical models when compared to approved anti-PD-1 and PD-L1 therapies and warrants its evaluation in patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
- Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
- Compass Therapeutics presents data on combination of CTX-009, CTX-471
- Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update